ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Completed · Phase 2
Conditions studied: Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
In brief
Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare: 1. the incidence, magnitude and duration of CMV and EBV viremia in the first year after transplant. 2. the side effects of the anti-viral drugs requiring dose reduction or cessation In addition, we will test renal tissue obtained from any biopsies post-transplant (surveillance or clinically indicated biopsies) by both polymerase chain reaction (PCR) and fluorescence in situ hybridization to assess for latent CMV and/or EBV.
Key facts
- Study ID
- NCT01972035
- Run by
- University of Minnesota
- People needed
- 137
- Starts
- 2014-08-01
- Expected to finish
- 2021-02-28
- Last updated by the study team
- 2022-04-12
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All consenting kidney transplant recipients.
You may not qualify if…
- Non-consent.
- Recipients with allergies to valacyclovir or valganciclovir
- Recipients that are unable to independently understand the consent form and do not have a legally authorized representative.
Where it is running
- University of MN — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.